medac GmbH is a privately-owned pharmaceutical company based in Wedel, near Hamburg, Germany. Founded in 1970, it has grown into a globally operating firm with over 2,000 employees and annual turnover of €620 million. The company develops, manufactures, and distributes pharmaceutical products - including original products, generics, biosimilars, and diagnostics - across more than 90 countries. In 2023/24 alone, medac assembled and packaged 48 million units, including 9 million pens and 10 million syringes, maintaining a 98% delivery capability.
For cybersecurity professionals, the threat surface here is broad and consequential. A pharmaceutical manufacturer shipping to 90+ countries handles sensitive data at every node: proprietary R&D, clinical trial information, manufacturing process controls, supply chain logistics, and patient-facing diagnostics. The operational technology layer - automated assembly lines, packaging systems, quality control instrumentation - represents a converged IT/OT environment where a breach means more than data loss; it means disrupted production of essential medicines.
medac has stated a commitment to making essential treatments available worldwide, especially in areas of unmet therapeutic need. That mission depends on operational resilience. Securing a global pharmaceutical supply chain of this scale requires defending against IP exfiltration, ransomware targeting manufacturing uptime, and compliance pressures across multiple regulatory jurisdictions. The team operates at the intersection of advanced technology and precision manufacturing - where the security posture has direct, measurable downstream effects on patients.
